Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (symbol: KURA) is a clinical-stage biopharmaceutical company based in San Diego, dedicated to pioneering precision medicines for cancer treatment. Leveraging advances in cancer genomics, Kura develops targeted therapies and companion diagnostics designed to address the genetic underpinnings of various cancers, optimizing treatment efficacy and safety.
The company's flagship product candidate, Tipifarnib, is under investigation for treating both solid tumors and blood cancers. Tipifarnib is a potent farnesyl transferase inhibitor, currently undergoing Phase 1/2 trials in combination with alpelisib for patients with head and neck squamous cell carcinoma.
Another key candidate, Ziftomenib, targets acute myeloid leukemia (AML) with NPM1 and KMT2A mutations. Highlighted by its recent Breakthrough Therapy Designation from the FDA, Ziftomenib is involved in multiple clinical trials, including the KOMET-001 and KOMET-007 studies. Early results show promising efficacy and a favorable safety profile, particularly in the combination with current standards of care like venetoclax and azacitidine.
Kura is also advancing KO-2806, a next-generation farnesyl transferase inhibitor, in a Phase 1 dose-escalation trial as a monotherapy and in combination with other targeted therapies for renal and lung cancers.
Financially, Kura remains robust, with cash reserves projected to support operations through 2027. The company has an ongoing commitment to aggressive research, development, and pre-commercial activities, ensuring continued progression of its promising pipeline.
The company's recent achievements include reporting preliminary clinical data from the KOMET-007 trial and securing additional financing to reinforce its financial position. Kura continues its mission to bring life-saving therapies to patients with high unmet medical needs, aiming to improve and extend the lives of those battling cancer.
Kura Oncology, Inc. (Nasdaq: KURA) announced the appointment of Dr. Helen Collins to its board of directors. Dr. Collins, a veteran in medical oncology with over 25 years of experience, previously served as Chief Medical Officer at Five Prime Therapeutics. Her expertise will be instrumental as Kura advances its pipeline, including the KO-539 menin inhibitor in acute myeloid leukemia and the tipifarnib program for HRAS mutant head and neck squamous cell carcinoma. This strategic addition aims to enhance Kura's clinical development efforts and fulfill its mission of precision cancer therapies.
Kura Oncology, Inc. announced a clinical collaboration with Novartis to study the combination of tipifarnib and alpelisib for treating head and neck squamous cell carcinoma (HNSCC) driven by HRAS or PIK3CA pathways. This follows promising preclinical results indicating enhanced anti-tumor activity when both drugs target co-dependent pathways. The Phase 1/2 KURRENT trial is set to commence in the second half of 2021, aiming to potentially broaden tipifarnib's application among advanced HNSCC patients. Kura retains global rights to tipifarnib.
Kura Oncology announced the dosing of the first patient in the Phase 1b expansion of KOMET-001, targeting relapsed/refractory acute myeloid leukemia (AML) with its selective menin inhibitor, KO-539. The trial includes two cohorts: 200 mg and 600 mg doses, each enrolling at least 12 genetically enriched patients. KO-539 showed promising activity and a favorable safety profile in prior phases. The data obtained will aid in determining the recommended Phase 2 dose and potentially contribute to registration efforts. Kura aims to present future data at medical meetings.
Kura Oncology (Nasdaq: KURA) announced its participation in the JMP Securities Life Sciences Conference, with CEO Troy Wilson scheduled for a virtual presentation on June 17, 2021, at 3:00 p.m. ET. The live audio webcast will be accessible on Kura's website, with a replay available afterward. Kura focuses on precision medicines for cancer treatment, with promising candidates like KO-539 and Tipifarnib in clinical trials targeting specific cancers, including acute myeloid leukemia and HRAS mutant head and neck cancer.
Kura Oncology (Nasdaq: KURA) announced the appointment of Carol Schafer to its board of directors, effective June 3, 2021. With over 25 years of experience in healthcare investment banking, including her recent role as Vice Chair of Equity Capital Markets at Wells Fargo Securities, Schafer is expected to contribute significantly to Kura’s strategic initiatives. She will succeed Robert Hoffman, who is stepping down from the board on August 3, 2021, after six years of service. Kura's pipeline includes promising cancer treatment candidates like KO-539 and Tipifarnib.
Kura Oncology, a clinical-stage biopharmaceutical company focused on cancer treatments, announced its participation in the Cowen 2nd Annual Virtual Oncology Innovation Summit. CEO Troy Wilson will present in a fireside chat on May 20, 2021, at 10:20 a.m. PT. A live audio webcast will be available on the company's website, with a replay following the event. Kura's pipeline includes KO-539, a menin inhibitor in a Phase 1/2 trial, and Tipifarnib, a farnesyl transferase inhibitor with Breakthrough Therapy Designation, currently in a registration-directed study for head and neck cancer.
Kura Oncology reported its Q1 2021 financial results, highlighting the promising clinical activity and safety profile of its menin inhibitor KO-539. The KOMET-001 trial has been amended to include Phase 1b expansion cohorts for NPM1-mutant and KMT2A-rearranged relapsed/refractory AML patients. Kura maintains a solid financial position with $603.9 million in cash, expected to fund operations into 2024. The company also announced a publication of tipifarnib trial data in the Journal of Clinical Oncology and received Breakthrough Device Designation for an HRAS companion diagnostic.
Kura Oncology (KURA) will report its Q1 2021 financial results on May 6, 2021, after the U.S. markets close. A conference call will follow at 4:30 p.m. ET to discuss the results and provide a corporate update. The call can be accessed by dialing the provided numbers. Kura focuses on precision cancer treatments, with notable therapies in its pipeline, including KO-539 for acute myeloid leukemia and Tipifarnib for HRAS mutant head and neck cancer, which has received Breakthrough Therapy Designation.
Kura Oncology reported significant results from the Phase 2 RUN-HN trial of tipifarnib for HRAS mutant head and neck squamous cell carcinoma (HNSCC). The objective response rate (ORR) was 55%, with a median progression-free survival (PFS) of 5.6 months, outperforming previous therapies which had a PFS of 3.6 months (p=0.0012). The median overall survival (OS) was recorded at 15.4 months. The safety profile was consistent with earlier data, supporting the advancement of the AIM-HN registration-directed trial. These findings underscore the potential of genomic testing in identifying suitable candidates for tipifarnib treatment.
Kura Oncology reported positive developments regarding its clinical pipeline and financial results for 2020. Preliminary data for KO-539 showed significant single-agent activity in relapsed AML patients, particularly those with NPM1 mutations. The FDA granted Breakthrough Therapy Designation to tipifarnib for treating recurrent HRAS mutant HNSCC. Financially, the company ended 2020 with $633.3 million in cash, ensuring operational funding into 2024. However, Kura also reported an increase in net losses, reaching $89.6 million for the year.
FAQ
What is the current stock price of Kura Oncology (KURA)?
What is the market cap of Kura Oncology (KURA)?
What is Kura Oncology's core business?
What are the main product candidates of Kura Oncology?
What is Tipifarnib used for?
What recent achievements has Kura Oncology reported?
What is Ziftomenib?
How is Ziftomenib being tested currently?
What financial position is Kura Oncology in?
What is KO-2806?
Where is Kura Oncology based?
How can investors get in touch with Kura Oncology?
